Role of Motility-related Protein-1 in Promoting the Development of Several Types of Cancer (Review)

Overview

Journal Oncol Lett

Specialty Oncology

Date 2014 Feb 13

PMID 24520284

Citations 1

Authors

Han Xuan

Xiaotong Hu

Jinwen Huang

Affiliations

Soon will be listed here.

Abstract

Motility-related protein-1 (CD9), a type of cell surface glycoprotein comprising a four-pass transmembrane domain that forms multimeric complexes with other cell surface proteins, belongs to the tetraspanins family. From previous studies, we know that CD9 is considered to function primarily as a progression and metastasis suppressor in a variety of cancers, including breast, non-small cell lung colon and myeloma. However, an expanding body of literature has shown the contradictory outcome that tetraspanin CD9 is also vital in promoting cancer progression in several types of cancer. This review summarizes the recent studies on CD9 and concludes that it does not always act as a progression and metastasis suppressor. Conversely, in specific cases, CD9 may promote tumor progression through the following three aspects: Facilitating tumor cell transmigration, increasing tumor cell motility and hastening the growth of some cancers. In addition, CD9 appears to be an important marker of cancer stem cells in certain types of tumor.

Citing Articles

Podoplanin in Inflammation and Cancer.

Quintanilla M, Montero-Montero L, Renart J, Martin-Villar E Int J Mol Sci. 2019; 20(3).

PMID: 30736372 PMC: 6386838. DOI: 10.3390/ijms20030707.

References

Ikeyama S, Koyama M, Yamaoko M, Sasada R, Miyake M . Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med. 1993; 177(5):1231-7. PMC: 2191011. DOI: 10.1084/jem.177.5.1231. View

Hwang J, Jo K, Lee Y, Sung B, Park Y, Lee J . Upregulation of CD9 in ovarian cancer is related to the induction of TNF-α gene expression and constitutive NF-κB activation. Carcinogenesis. 2011; 33(1):77-83. DOI: 10.1093/carcin/bgr257. View

Berditchevski F . Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci. 2001; 114(Pt 23):4143-51. DOI: 10.1242/jcs.114.23.4143. View

Oritani K, Aoyama K, Tomiyama Y, Kincade P, Matsuzawa Y . Stromal cell CD9 and the differentiation of hematopoietic stem/progenitor cells. Leuk Lymphoma. 2000; 38(1-2):147-52. DOI: 10.3109/10428190009060328. View

Mitsuzuka K, Handa K, Satoh M, Arai Y, Hakomori S . A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9. J Biol Chem. 2005; 280(42):35545-53. DOI: 10.1074/jbc.M505630200. View

Hori H, Yano S, Koufuji K, Takeda J, Shirouzu K . CD9 expression in gastric cancer and its significance. J Surg Res. 2004; 117(2):208-15. DOI: 10.1016/j.jss.2004.01.014. View

Boucheix C, Soria C, Mirshahi M, Soria J, Perrot J, Fournier N . Characteristics of platelet aggregation induced by the monoclonal antibody ALB6 (acute lymphoblastic leukemia antigen p 24). Inhibition of aggregation by ALB6Fab. FEBS Lett. 1983; 161(2):289-95. DOI: 10.1016/0014-5793(83)81027-8. View

Miyake M, Koyama M, Seno M, Ikeyama S . Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility. J Exp Med. 1991; 174(6):1347-54. PMC: 2119050. DOI: 10.1084/jem.174.6.1347. View

Kischel P, Bellahcene A, Deux B, Lamour V, Dobson R, De Pauw E . Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases. Anticancer Res. 2012; 32(12):5211-20. View

10.

Higashiyama M, Doi O, Kodama K, Yokouchi H, Adachi M, Huang C . Immunohistochemically detected expression of motility-related protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis. Int J Cancer. 1997; 74(2):205-11. DOI: 10.1002/(sici)1097-0215(19970422)74:2<205::aid-ijc12>3.0.co;2-c. View

11.

Chambrion C, Le Naour F . The tetraspanins CD9 and CD81 regulate CD9P1-induced effects on cell migration. PLoS One. 2010; 5(6):e11219. PMC: 2888588. DOI: 10.1371/journal.pone.0011219. View

12.

Huang C, Ueno M, Liu D, Masuya D, Nakano J, Yokomise H . MRP-1/CD9 gene transduction regulates the actin cytoskeleton through the downregulation of WAVE2. Oncogene. 2006; 25(49):6480-8. DOI: 10.1038/sj.onc.1209654. View

13.

De Bruyne E, Andersen T, De Raeve H, Van Valckenborgh E, Caers J, Van Camp B . Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients. Leukemia. 2006; 20(10):1870-9. DOI: 10.1038/sj.leu.2404343. View

14.

Biermann K, Heukamp L, Steger K, Zhou H, Franke F, Guetgemann I . Gene expression profiling identifies new biological markers of neoplastic germ cells. Anticancer Res. 2007; 27(5A):3091-100. View

15.

Horvath G, Serru V, Clay D, Billard M, Boucheix C, Rubinstein E . CD19 is linked to the integrin-associated tetraspans CD9, CD81, and CD82. J Biol Chem. 1998; 273(46):30537-43. DOI: 10.1074/jbc.273.46.30537. View

16.

Castro-Sanchez L, Soto-Guzman A, Navarro-Tito N, Martinez-Orozco R, Salazar E . Native type IV collagen induces cell migration through a CD9 and DDR1-dependent pathway in MDA-MB-231 breast cancer cells. Eur J Cell Biol. 2010; 89(11):843-52. DOI: 10.1016/j.ejcb.2010.07.004. View

17.

Iwasaki T, Takeda Y, Maruyama K, Yokosaki Y, Tsujino K, Tetsumoto S . Deletion of tetraspanin CD9 diminishes lymphangiogenesis in vivo and in vitro. J Biol Chem. 2012; 288(4):2118-31. PMC: 3554885. DOI: 10.1074/jbc.M112.424291. View

18.

Zvereff V, Wang J, Shun K, Lacoste J, Chevrette M . Colocalisation of CD9 and mortalin in CD9-induced mitotic catastrophe in human prostate cancer cells. Br J Cancer. 2007; 97(7):941-8. PMC: 2360413. DOI: 10.1038/sj.bjc.6603964. View

19.

Kamisasanuki T, Tokushige S, Terasaki H, Khai N, Wang Y, Sakamoto T . Targeting CD9 produces stimulus-independent antiangiogenic effects predominantly in activated endothelial cells during angiogenesis: a novel antiangiogenic therapy. Biochem Biophys Res Commun. 2011; 413(1):128-35. DOI: 10.1016/j.bbrc.2011.08.068. View

20.

Zoller M . Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2008; 9(1):40-55. DOI: 10.1038/nrc2543. View